Click here to get full coverage on Will Lexeo Therapeutics (NASDAQ:LXEO) Spend Its Cash Wisely? - Yahoo Finance

Will Lexeo Therapeutics (NASDAQ:LXEO) Spend Its Cash Wisely?  Yahoo Finance

Will Lexeo Therapeutics (NASDAQ:LXEO) Spend Its Cash Wisely? - Yahoo Finance

Click here to get full coverage on Lexeo says cash lasts into 2028 as pivotal gene therapy trial nears - Stock Titan

Lexeo says cash lasts into 2028 as pivotal gene therapy trial nears  Stock Titan

Lexeo says cash lasts into 2028 as pivotal gene therapy trial nears - Stock Titan

Click here to get full coverage on Analysts Offer Insights on Healthcare Companies: Lexeo Therapeutics, Inc. (LXEO), Bicara Therapeutics Inc. (BCAX) and Compass Therapeutics (CMPX) - The Globe and Mail

Analysts Offer Insights on Healthcare Companies: Lexeo Therapeutics, Inc. (LXEO), Bicara Therapeutics Inc. (BCAX) and Compass Therapeutics (CMPX)  The Globe and Mail

Analysts Offer Insights on Healthcare Companies: Lexeo Therapeutics, Inc. (LXEO), Bicara Therapeutics Inc. (BCAX) and Compass Therapeutics (CMPX) - The Globe and Mail

Click here to get full coverage on LXEO: 2025 net loss was $100M; cash reserves of $246.6M support pipeline and operations into 2028 - TradingView

LXEO: 2025 net loss was $100M; cash reserves of $246.6M support pipeline and operations into 2028  TradingView

LXEO: 2025 net loss was $100M; cash reserves of $246.6M support pipeline and operations into 2028 - TradingView

Click here to get full coverage on LXEO Surges 7.6% Without Clear Catalyst or Volume - bitget.com

LXEO Surges 7.6% Without Clear Catalyst or Volume  bitget.com

LXEO Surges 7.6% Without Clear Catalyst or Volume - bitget.com

Click here to get full coverage on Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Rating of "Moderate Buy" by Analysts  MarketBeat

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat

Click here to get full coverage on Lexeo Therapeutics (LXEO) Gets a PT Cut to $13 by H.C. Wainwright Due to Equity Raise - MSN

Lexeo Therapeutics (LXEO) Gets a PT Cut to $13 by H.C. Wainwright Due to Equity Raise  MSN

Lexeo Therapeutics (LXEO) Gets a PT Cut to $13 by H.C. Wainwright Due to Equity Raise - MSN

Click here to get full coverage on Lexeo Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights - ChartMill

Lexeo Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights  ChartMill

Lexeo Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights - ChartMill

Click here to get full coverage on Oppenheimer Maintains Lexeo Therapeutics(LXEO.US) With Buy Rating, Maintains Target Price $20 - 富途牛牛

Oppenheimer Maintains Lexeo Therapeutics(LXEO.US) With Buy Rating, Maintains Target Price $20  富途牛牛

Oppenheimer Maintains Lexeo Therapeutics(LXEO.US) With Buy Rating, Maintains Target Price $20 - 富途牛牛

Click here to get full coverage on LEXEO THERAPEUTICS Q4 2025 Earnings Preview: Recent $LXEO Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative

LEXEO THERAPEUTICS Q4 2025 Earnings Preview: Recent $LXEO Insider Trading, Hedge Fund Activity, and More  Quiver Quantitative

LEXEO THERAPEUTICS Q4 2025 Earnings Preview: Recent $LXEO Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative

Click here to get full coverage on Institutional investors have a lot riding on Lexeo Therapeutics, Inc. (NASDAQ:LXEO) with 56% ownership - simplywall.st

Institutional investors have a lot riding on Lexeo Therapeutics, Inc. (NASDAQ:LXEO) with 56% ownership  simplywall.st

Institutional investors have a lot riding on Lexeo Therapeutics, Inc. (NASDAQ:LXEO) with 56% ownership - simplywall.st

Click here to get full coverage on Runway into 2028 as Lexeo (NASDAQ: LXEO) pushes pivotal cardiac gene therapies - Stock Titan

Runway into 2028 as Lexeo (NASDAQ: LXEO) pushes pivotal cardiac gene therapies  Stock Titan

Runway into 2028 as Lexeo (NASDAQ: LXEO) pushes pivotal cardiac gene therapies - Stock Titan

Click here to get full coverage on Wall Street Rallies Behind Lexeo Therapeutics (LXEO)’s Gene Therapy Pipeline - Yahoo Finance

Wall Street Rallies Behind Lexeo Therapeutics (LXEO)’s Gene Therapy Pipeline  Yahoo Finance

Wall Street Rallies Behind Lexeo Therapeutics (LXEO)’s Gene Therapy Pipeline - Yahoo Finance

Click here to get full coverage on Lexeo Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary - TradingView

Lexeo Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary  TradingView

Lexeo Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary - TradingView

Click here to get full coverage on Gene therapy advances at Lexeo Therapeutics (NASDAQ: LXEO) target heart disease - Stock Titan

Gene therapy advances at Lexeo Therapeutics (NASDAQ: LXEO) target heart disease  Stock Titan

Gene therapy advances at Lexeo Therapeutics (NASDAQ: LXEO) target heart disease - Stock Titan

Click here to get full coverage on [Form 4] Lexeo Therapeutics, Inc. Insider Trading Activity - Stock Titan

[Form 4] Lexeo Therapeutics, Inc. Insider Trading Activity  Stock Titan

[Form 4] Lexeo Therapeutics, Inc. Insider Trading Activity - Stock Titan

Click here to get full coverage on Is Lexeo Therapeutics (LXEO) One of Billionaire Daniel Sundheim’s Stock Picks with Huge Upside Potential - Yahoo Finance

Is Lexeo Therapeutics (LXEO) One of Billionaire Daniel Sundheim’s Stock Picks with Huge Upside Potential  Yahoo Finance

Is Lexeo Therapeutics (LXEO) One of Billionaire Daniel Sundheim’s Stock Picks with Huge Upside Potential - Yahoo Finance

Click here to get full coverage on Vanguard realignment leads to separate LXEO holdings reporting (LXEO) - Stock Titan

Vanguard realignment leads to separate LXEO holdings reporting (LXEO)  Stock Titan

Vanguard realignment leads to separate LXEO holdings reporting (LXEO) - Stock Titan

Click here to get full coverage on LXEO Stock Price and Chart — NASDAQ:LXEO - TradingView

LXEO Stock Price and Chart — NASDAQ:LXEO  TradingView

LXEO Stock Price and Chart — NASDAQ:LXEO - TradingView

Click here to get full coverage on Lexeo Therapeutics (LXEO) CEO acquires 2,623 shares via employee stock plan - Stock Titan

Lexeo Therapeutics (LXEO) CEO acquires 2,623 shares via employee stock plan  Stock Titan

Lexeo Therapeutics (LXEO) CEO acquires 2,623 shares via employee stock plan - Stock Titan

Click here to get full coverage on Wall Street Analysts See a 108.23% Upside in Lexeo Therapeutics, Inc. (LXEO): Can the Stock Really Move This High? - Yahoo Finance

Wall Street Analysts See a 108.23% Upside in Lexeo Therapeutics, Inc. (LXEO): Can the Stock Really Move This High?  Yahoo Finance

Wall Street Analysts See a 108.23% Upside in Lexeo Therapeutics, Inc. (LXEO): Can the Stock Really Move This High? - Yahoo Finance

Click here to get full coverage on New cardiology leaders join Lexeo as it backs novel cardiac RNA startup - Stock Titan

New cardiology leaders join Lexeo as it backs novel cardiac RNA startup  Stock Titan

New cardiology leaders join Lexeo as it backs novel cardiac RNA startup - Stock Titan

Click here to get full coverage on Owning 44% shares,institutional owners seem interested in Lexeo Therapeutics, Inc. (NASDAQ:LXEO), - Yahoo Finance

Owning 44% shares,institutional owners seem interested in Lexeo Therapeutics, Inc. (NASDAQ:LXEO),  Yahoo Finance

Owning 44% shares,institutional owners seem interested in Lexeo Therapeutics, Inc. (NASDAQ:LXEO), - Yahoo Finance

Click here to get full coverage on Lexeo Therapeutics (NASDAQ:LXEO) Shares Up 10.4% - What's Next? - MarketBeat

Lexeo Therapeutics (NASDAQ:LXEO) Shares Up 10.4% - What's Next?  MarketBeat

Lexeo Therapeutics (NASDAQ:LXEO) Shares Up 10.4% - What's Next? - MarketBeat

Click here to get full coverage on Stifel Maintains Buy Rating on Lexeo Therapeutics (LXEO) - Yahoo Finance

Stifel Maintains Buy Rating on Lexeo Therapeutics (LXEO)  Yahoo Finance

Stifel Maintains Buy Rating on Lexeo Therapeutics (LXEO) - Yahoo Finance

Click here to get full coverage on $LXEO stock is up 11% today. Here's what we see in our data. - Quiver Quantitative

$LXEO stock is up 11% today. Here's what we see in our data.  Quiver Quantitative

$LXEO stock is up 11% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Lexeo Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights - GlobeNewswire

Lexeo Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights  GlobeNewswire

Lexeo Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights - GlobeNewswire

Click here to get full coverage on Should I buy Lexeo Therapeutics, Inc. (LXEO) - Zacks Investment Research

Should I buy Lexeo Therapeutics, Inc. (LXEO)  Zacks Investment Research

Should I buy Lexeo Therapeutics, Inc. (LXEO) - Zacks Investment Research

Click here to get full coverage on $LXEO stock is down 4% today. Here's what we see in our data. - Quiver Quantitative

$LXEO stock is down 4% today. Here's what we see in our data.  Quiver Quantitative

$LXEO stock is down 4% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Is Lexeo Therapeutics (NASDAQ:LXEO) In A Good Position To Invest In Growth? - Yahoo Finance

Is Lexeo Therapeutics (NASDAQ:LXEO) In A Good Position To Invest In Growth?  Yahoo Finance

Is Lexeo Therapeutics (NASDAQ:LXEO) In A Good Position To Invest In Growth? - Yahoo Finance

Click here to get full coverage on Biotech Lexeo to stream Feb investor talks from New York and online - Stock Titan

Biotech Lexeo to stream Feb investor talks from New York and online  Stock Titan

Biotech Lexeo to stream Feb investor talks from New York and online - Stock Titan

Click here to get full coverage on Lexeo Therapeutics: Behind The Rebound (NASDAQ:LXEO) - Seeking Alpha

Lexeo Therapeutics: Behind The Rebound (NASDAQ:LXEO)  Seeking Alpha

Lexeo Therapeutics: Behind The Rebound (NASDAQ:LXEO) - Seeking Alpha

Click here to get full coverage on Is Lexeo Therapeutics (NASDAQ:LXEO) In A Good Position To Invest In Growth? - simplywall.st

Is Lexeo Therapeutics (NASDAQ:LXEO) In A Good Position To Invest In Growth?  simplywall.st

Is Lexeo Therapeutics (NASDAQ:LXEO) In A Good Position To Invest In Growth? - simplywall.st

Click here to get full coverage on 23% LVMI reduction at 12 months — Lexeo's LX2006 shows cardiac & neurologic improvement; FDA open to pooling - Stock Titan

23% LVMI reduction at 12 months — Lexeo's LX2006 shows cardiac & neurologic improvement; FDA open to pooling  Stock Titan

23% LVMI reduction at 12 months — Lexeo's LX2006 shows cardiac & neurologic improvement; FDA open to pooling - Stock Titan

Click here to get full coverage on New Analyst Forecast: $LXEO Given $10 Price Target | LXEO Stock News - Quiver Quantitative

New Analyst Forecast: $LXEO Given $10 Price Target | LXEO Stock News  Quiver Quantitative

New Analyst Forecast: $LXEO Given $10 Price Target | LXEO Stock News - Quiver Quantitative

Click here to get full coverage on Lexeo Therapeutics Reports Positive Interim Results from HEROIC-PKP2 Trial of LX2020 for Arrhythmogenic Cardiomyopathy - Quiver Quantitative

Lexeo Therapeutics Reports Positive Interim Results from HEROIC-PKP2 Trial of LX2020 for Arrhythmogenic Cardiomyopathy  Quiver Quantitative

Lexeo Therapeutics Reports Positive Interim Results from HEROIC-PKP2 Trial of LX2020 for Arrhythmogenic Cardiomyopathy - Quiver Quantitative

Click here to get full coverage on Lexeo Therapeutics | 10-K: Annual report - Moomoo

Lexeo Therapeutics | 10-K: Annual report  Moomoo

Lexeo Therapeutics | 10-K: Annual report - Moomoo

Click here to get full coverage on Lexeo Therapeutics Advances Cardiac Gene Therapies, Strengthens Finances - TipRanks

Lexeo Therapeutics Advances Cardiac Gene Therapies, Strengthens Finances  TipRanks

Lexeo Therapeutics Advances Cardiac Gene Therapies, Strengthens Finances - TipRanks

Click here to get full coverage on Lexeo Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants - Stock Titan

Lexeo Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants  Stock Titan

Lexeo Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants - Stock Titan

Click here to get full coverage on Lexeo: Maintaining Buy Rating Based On FDA Accelerated Approval Feedback (NASDAQ:LXEO) - Seeking Alpha

Lexeo: Maintaining Buy Rating Based On FDA Accelerated Approval Feedback (NASDAQ:LXEO)  Seeking Alpha

Lexeo: Maintaining Buy Rating Based On FDA Accelerated Approval Feedback (NASDAQ:LXEO) - Seeking Alpha

Click here to get full coverage on $LXEO stock is up 28% today. Here's what we see in our data. - Quiver Quantitative

$LXEO stock is up 28% today. Here's what we see in our data.  Quiver Quantitative

$LXEO stock is up 28% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on H.C. Wainwright lowers Lexeo Therapeutics stock price target on PKP2 data concerns - Investing.com

H.C. Wainwright lowers Lexeo Therapeutics stock price target on PKP2 data concerns  Investing.com

H.C. Wainwright lowers Lexeo Therapeutics stock price target on PKP2 data concerns - Investing.com

Click here to get full coverage on Lexeo Therapeutics stock falls 23% despite Cantor maintaining Overweight rating - Investing.com

Lexeo Therapeutics stock falls 23% despite Cantor maintaining Overweight rating  Investing.com

Lexeo Therapeutics stock falls 23% despite Cantor maintaining Overweight rating - Investing.com

Click here to get full coverage on Lexeo Therapeutics stock falls after PKP2 gene therapy data - Investing.com

Lexeo Therapeutics stock falls after PKP2 gene therapy data  Investing.com

Lexeo Therapeutics stock falls after PKP2 gene therapy data - Investing.com

Click here to get full coverage on Lexeo Therapeutics Announces Key Leadership Appointments - GlobeNewswire

Lexeo Therapeutics Announces Key Leadership Appointments  GlobeNewswire

Lexeo Therapeutics Announces Key Leadership Appointments - GlobeNewswire

Click here to get full coverage on Raymond James initiates Lexeo Therapeutics stock with Strong Buy rating - Investing.com

Raymond James initiates Lexeo Therapeutics stock with Strong Buy rating  Investing.com

Raymond James initiates Lexeo Therapeutics stock with Strong Buy rating - Investing.com

Click here to get full coverage on Cantor Fitzgerald reiterates Lexeo Therapeutics stock Overweight rating By Investing.com - Investing.com India

Cantor Fitzgerald reiterates Lexeo Therapeutics stock Overweight rating By Investing.com  Investing.com India

Cantor Fitzgerald reiterates Lexeo Therapeutics stock Overweight rating By Investing.com - Investing.com India

Click here to get full coverage on Oppenheimer reiterates Outperform rating on Lexeo Therapeutics stock - Investing.com

Oppenheimer reiterates Outperform rating on Lexeo Therapeutics stock  Investing.com

Oppenheimer reiterates Outperform rating on Lexeo Therapeutics stock - Investing.com

Click here to get full coverage on Lexeo Therapeutics appoints new COO and CMO, announces executive transition - Investing.com

Lexeo Therapeutics appoints new COO and CMO, announces executive transition  Investing.com

Lexeo Therapeutics appoints new COO and CMO, announces executive transition - Investing.com

Click here to get full coverage on Lexeo Therapeutics Announces Key Leadership Appointments to Drive Advances in Cardiovascular Medicine - Quiver Quantitative

Lexeo Therapeutics Announces Key Leadership Appointments to Drive Advances in Cardiovascular Medicine  Quiver Quantitative

Lexeo Therapeutics Announces Key Leadership Appointments to Drive Advances in Cardiovascular Medicine - Quiver Quantitative

Click here to get full coverage on Lexeo Therapeutics to Participate in the Leerink Global Healthcare Conference - GlobeNewswire

Lexeo Therapeutics to Participate in the Leerink Global Healthcare Conference  GlobeNewswire

Lexeo Therapeutics to Participate in the Leerink Global Healthcare Conference - GlobeNewswire

Click here to get full coverage on Lexeo Therapeutics, Inc. SEC 10-Q Report - TradingView

Lexeo Therapeutics, Inc. SEC 10-Q Report  TradingView

Lexeo Therapeutics, Inc. SEC 10-Q Report - TradingView

Click here to get full coverage on AI Investing Insights - Official Homepage - Intellectia AI™ - Intellectia AI

AI Investing Insights - Official Homepage - Intellectia AI™  Intellectia AI

AI Investing Insights - Official Homepage - Intellectia AI™ - Intellectia AI

Click here to get full coverage on Morning Market Movers: GLTO, CISS, SPRB, LXEO See Big Swings - RTTNews

Morning Market Movers: GLTO, CISS, SPRB, LXEO See Big Swings  RTTNews

Morning Market Movers: GLTO, CISS, SPRB, LXEO See Big Swings - RTTNews

Click here to get full coverage on Lexeo Therapeutics Stock Rallies On Discussions With FDA To Expedite Friedreich’s Ataxia Drug Approval Process - Stocktwits

Lexeo Therapeutics Stock Rallies On Discussions With FDA To Expedite Friedreich’s Ataxia Drug Approval Process  Stocktwits

Lexeo Therapeutics Stock Rallies On Discussions With FDA To Expedite Friedreich’s Ataxia Drug Approval Process - Stocktwits

Click here to get full coverage on Lexeo Therapeutics Announces Key Executive Leadership Changes - TipRanks

Lexeo Therapeutics Announces Key Executive Leadership Changes  TipRanks

Lexeo Therapeutics Announces Key Executive Leadership Changes - TipRanks

Click here to get full coverage on Lexeo Therapeutics Announces Pricing of Public Offering and Concurrent Private Placement - Yahoo Finance

Lexeo Therapeutics Announces Pricing of Public Offering and Concurrent Private Placement  Yahoo Finance

Lexeo Therapeutics Announces Pricing of Public Offering and Concurrent Private Placement - Yahoo Finance

Click here to get full coverage on Lexeo Therapeutics to Participate in Upcoming Investor Conferences in February - GlobeNewswire

Lexeo Therapeutics to Participate in Upcoming Investor Conferences in February  GlobeNewswire

Lexeo Therapeutics to Participate in Upcoming Investor Conferences in February - GlobeNewswire

Click here to get full coverage on Lexeo Therapeutics Announces Closing of Public Offering and - GlobeNewswire

Lexeo Therapeutics Announces Closing of Public Offering and  GlobeNewswire

Lexeo Therapeutics Announces Closing of Public Offering and - GlobeNewswire

Click here to get full coverage on Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy - ChartMill

Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy  ChartMill

Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy - ChartMill

Click here to get full coverage on LXEO Stock Price, News & Analysis - Stock Titan

LXEO Stock Price, News & Analysis  Stock Titan

LXEO Stock Price, News & Analysis - Stock Titan

Click here to get full coverage on Lexeo Therapeutics Announces Positive Interim Phase I/II - GlobeNewswire

Lexeo Therapeutics Announces Positive Interim Phase I/II  GlobeNewswire

Lexeo Therapeutics Announces Positive Interim Phase I/II - GlobeNewswire

Click here to get full coverage on Why Lexeo Therapeutics (LXEO) Skyrocketed on Monday? - Yahoo Finance

Why Lexeo Therapeutics (LXEO) Skyrocketed on Monday?  Yahoo Finance

Why Lexeo Therapeutics (LXEO) Skyrocketed on Monday? - Yahoo Finance

Click here to get full coverage on Lexeo Therapeutics Announces FDA Support for Accelerated Approval Pathway, Positive Interim Data for Gene Therapy LX2006 - Yahoo Finance

Lexeo Therapeutics Announces FDA Support for Accelerated Approval Pathway, Positive Interim Data for Gene Therapy LX2006  Yahoo Finance

Lexeo Therapeutics Announces FDA Support for Accelerated Approval Pathway, Positive Interim Data for Gene Therapy LX2006 - Yahoo Finance

Click here to get full coverage on Lexeo Therapeutics Announces $80 Million Equity Financing - GlobeNewswire

Lexeo Therapeutics Announces $80 Million Equity Financing  GlobeNewswire

Lexeo Therapeutics Announces $80 Million Equity Financing - GlobeNewswire

Click here to get full coverage on Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights - GlobeNewswire

Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights  GlobeNewswire

Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights - GlobeNewswire

Click here to get full coverage on symbol__ Stock Quote Price and Forecast - CNN

symbol__ Stock Quote Price and Forecast  CNN

LXEO

Price Chart

Key Statistics

Technicals

About LXEO

Latest News

Will Lexeo Therapeutics (NASDAQ:LXEO) Spend Its Cash Wisely? - Yahoo Finance

Lexeo says cash lasts into 2028 as pivotal gene therapy trial nears - Stock Titan

Analysts Offer Insights on Healthcare Companies: Lexeo Therapeutics, Inc. (LXEO), Bicara Therapeutics Inc. (BCAX) and Compass Therapeutics (CMPX) - The Globe and Mail

Advanced Charts

Top Gainers

Top Losers